Clinical Trials Logo
  1. Home
  2. Ebola
  3. NCT05301504

A Study in Tanzania of a New Vaccine Against Two Types of Ebola

Ebola Clinical Trial

Official title:
A Phase Ib Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in Tanzanian Healthy Adult Volunteers

Clinical Trial Summary

An open label, first in human, non-randomised, dose escalation, single centre, phase Ib clinical trial

Clinical Trial Description

This is an open label, first in human, dose escalation, phase Ib clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 biEBOV vaccine in healthy Tanzanian volunteers aged 18-45. The vaccine will be administered intramuscularly (IM). There will be 4 study groups and it is anticipated that a total of 76 volunteers will be enrolled. Dose escalation and sentinel participant procedures will be implemented. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be sequentially allocated to a study group by selecting eligible volunteers for enrolment following screening. Sequential allocation will occur based on the order in which volunteers are enrolled. Group 4 will be recruited last, with dose selection being dependent on completion of groups 1-3 and a review of safety data. The trial is funded by Innovate UK project reference 971615. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05301504
Study type Interventional
Source University of Oxford
Contact
Status Active, not recruiting
Phase Phase 1
Start date March 30, 2022
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Completed NCT02240875 - A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo Phase 1
Completed NCT05064956 - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Phase 2
Completed NCT05079750 - A Study of a New Vaccine Against Two Types of Ebola Phase 1
Completed NCT04385719 - Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy Phase 2
Completed NCT00646152 - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study Phase 1
Completed NCT02818582 - GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Phase 2
Completed NCT02370589 - Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects Phase 1
Completed NCT04228783 - A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants Phase 3
Active, not recruiting NCT03031912 - African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Phase 2